Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Dec 2017 10:17

RNS Number : 0902Z
Physiomics PLC
12 December 2017
Β 

12th December 2017

Physiomics plc

("Physiomics") or ("the Company")

Β 

Director Dealing

Β 

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:

Β 

Director

Number of shares sold

Sale price per share

Dr J Millen, CEO

240,000

8.3p

Dr C Chassagnole, COO

600,000

8.3p

Β 

Following the sales of shares, the total holdings of each Director of the Company will be as follows:

Β 

Dr Paul Harper 525,707

Dr Jim Millen 444,641

Dr Christophe Chassagnole 417,008

Β 

The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary share

Β 

Β 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

240,000

d)

Aggregated information

- Aggregated volume

- Price

Β 

240,000

At 8.3p per share

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

Β 

Β 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary share

Β 

Β 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

600,000

d)

Aggregated information

- Aggregated volume

- Price

Β 

600,000

At 8.3p

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

Β 

Β 

Β 

Β 

Β 

Enquiries:

Β 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Β 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

Β 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Β 

Β 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHTTBMTMBBBBIR
Date   Source Headline
28th Apr 20202:50 pmRNSConference attendance and presentation
16th Apr 20207:00 amRNSConfirmation of Twitter account
9th Apr 202012:28 pmRNSHolding(s) in Company
6th Apr 20207:00 amRNSAwarded further Bicycle Therapeutics contract
19th Mar 20207:00 amRNSCOVID-19 update
10th Mar 20207:00 amRNSNIHR i4i award
5th Mar 20207:00 amRNSPhysiomics awarded further contract by Merck
3rd Mar 20207:00 amRNSAwarded two further contracts by Bicycle
27th Dec 20193:45 pmRNSHolding(s) in Company
23rd Dec 20197:00 amRNSContract award
20th Dec 201910:30 amRNSMerck Contracts
19th Nov 201912:52 pmRNSResult of AGM
21st Oct 20197:00 amRNSDispatch of Annual Report and Notice of AGM
30th Sep 20197:00 amRNSFinal Results for the Year Ended 30 June 2019
5th Aug 20197:00 amRNSDirector Dealing
30th Jul 20197:00 amRNSTrading Update
22nd Jul 20199:03 amRNSHolding(s) in Company
8th Jul 20197:00 amRNSAgreement with Bicycle and Cancer Research UK
2nd Jul 20191:30 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSContract Award
31st May 20197:00 amRNSChange of Adviser
14th May 20197:00 amRNSInnovate UK Award Project
3rd May 201912:00 pmRNSPhysiomics participates at NIHR event
30th Apr 20192:00 pmRNSConference attendance and presentation
27th Mar 20191:00 pmRNSIssue of Options
26th Mar 20191:00 pmRNSAIM Rule 26 Website Change
20th Mar 20197:00 amRNSConference Attendance and Presentation
21st Feb 20197:00 amRNSInterim Results
7th Jan 20197:00 amRNSConference Attendance
3rd Jan 20197:00 amRNSStrategic Collaboration
17th Dec 20187:00 amRNSRenewal of Agreement with Merck
20th Nov 201812:56 pmRNSResult of AGM
15th Oct 20181:00 pmRNSDispatch of Annual Report and Shareholder Circular
8th Oct 20187:00 amRNSFinal Results for the Year Ended 30 June 2018
9th Aug 20187:00 amRNSContract award
2nd Jul 20181:57 pmRNSPhysiomics Expands Technical Team
21st Jun 20187:00 amRNSTrading Update
11th Jun 20184:05 pmRNSUpdated Website
23rd May 20187:00 amRNSPlacing
26th Apr 201811:06 amRNSContract Award
6th Apr 20182:40 pmRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSPhysiomics to Present at AACR Annual Meeting
27th Mar 20185:23 pmRNSIssue of Options
14th Mar 20187:00 amRNSAward of New Innovate UK Grant
12th Mar 20187:00 amRNSCompletion of Innovate UK Grant Project
19th Feb 20187:00 amRNSInterim Results Statement
9th Feb 20187:00 amRNSContract Award
26th Jan 20187:00 amRNSNew Major Pharmaceutical Client
25th Jan 20181:34 pmRNSHolding(s) in Company
24th Jan 20188:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.